News Archive

Kubanda Cryotherapy cofounder Bailey Surtees was building the foundation for her company as an undergraduate at Johns Hopkins University (JHU) before she knew it. In 2016, she was researching how to make breast cancer treatment more affordable and accessible for low- and middle-income countries. Surtees surmised that cryotherapy was the ideal solution because it doesn’t require a sterile operating room or anesthesia. Thus, she began developing a probe that could be used for this treatment.

Image:  The team behind TEDCO’s Maryland Innovation Initiative. (Courtesy photo)

A $1.6 million grant has been awarded to the state of Maryland from the Economic Development Administration’s American Rescue Plan.

The federal funding will go towards the Maryland Economic Adjustment Fund (MEAF), administered by the Maryland Department of Commerce, and will be used to assist underserved small businesses across the state.

The MEAF revolving loan fund will serve businesses that do not qualify for traditional financing or lending sources. According to the EDA, this investment could help create 250 new jobs and generate a private investment of $210,000 in Maryland.

GAITHERSBURG, Md. and MIAMI, July 07, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (“Ridgeback Bio”), a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to expand the availability of Ebanga™ (Ansuvimab-zykl). Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga™ in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga™, ensuring it remains available to patients in endemic countries free of charge through Ridgeback Bio’s compassionate use program. Ebanga™ was approved by the U.S. Food and Drug Administration (FDA) in December 2020 for the treatment of Ebola.

AMPEL BioSolutions’ Precision Medicine Breakthrough AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning CHARLOTTESVILLE, Va., July 6, 2022 — AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer.  Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual’s gene expression and provide clinical decision support to physicians for treatment options for their patients.  The technology, only a concept for the last few years, is being utilized to launch a portfolio of 10+ clinical tests over the next five years to provide decision support for diseases that affect more than 50 million Americans.

The recent BIO International Convention not only brought showcasing opportunities for the state and its unparalleled life sciences assets, but also several exciting announcements from Maryland-based companies.

Horizon Therapeutics, a global biotech business focused on addressing autoimmune and inflammatory diseases, is working on quadrupling its space in Montgomery County. The company currently has a new state-of-the-art lab under construction with completion planned for 2024. Horizon anticipates doubling its employees in Maryland, with room in the new facility for more than 200 scientists.

The TABA Needs Assessment Report provides a third party, unbiased assessment of a Phase I project’s progress in technical and business areas that are critical to success in the competitive healthcare marketplace. There is no cost for this report and the time commitment for participation is minimal.

The Needs Assessment Report helps companies strategize for the project’s next steps. It analyzes the current state of your Phase I project and identifies strengths and weaknesses across four categories.

A new international partnership has formed between the state of Maryland and the Republic of Ireland.

As a result of Governor Hogan’s trade mission to France and Ireland, Maryland and the Guinness Enterprise Centre are teaming up to provide business assistance and expansion opportunities to companies at home and abroad. The partnership will also focus on academics and networking opportunities between the regions, by connecting local talent at universities to work directly with innovative start-ups.

Crab Trap 2022 applications are being accepted through August 31st! Entrepreneurs with innovative diagnostics, medical devices, therapeutics, or other transformative health solutions are invited to apply to the 7th annual BioHealth Capital Region Crab Trap pitch competition. Finalists for the 2022 Crab Trap competition will pitch IN PERSON on September 21st as part of the BioHealth Capital Region Investor Conference. The winning teams will receive cash prizes from our sponsors.

Applications are due by 5pm on Wednesday, August 31st.
Crab Trap finalists will be notified the week of 9/5/22. Mandatory virtual pitch coaching for all finalists will take place the week of 9/12/22.